David Hirsch, Alpha-9 Theranostics CEO

Tar­get­ed ra­dio­ther­a­py biotech out of Lon­gi­tude Cap­i­tal rais­es a fresh $75M

Al­pha-9 Ther­a­nos­tics, a tar­get­ed ra­dio­ther­a­py biotech launched out of Lon­gi­tude Cap­i­tal last year, has raised $75 mil­lion in a Se­ries B round.

In­ter­est­ing­ly, how­ev­er, the Van­cou­ver- and Boston-based biotech doesn’t have one lead can­di­date. Rather, it has five that it plans to take in­to ear­ly hu­man test­ing be­fore mov­ing for­ward with for­mal tri­als.

“We’re tak­ing them all in­to the clin­ic,” Al­pha-9 CEO and Lon­gi­tude Cap­i­tal ven­ture part­ner David Hirsch told End­points News. “And then based on the imag­ing and dosime­try da­ta, we’ll pick from that which we ad­vance in­to clin­i­cal tri­als, which is re­al­ly where costs start to ac­cel­er­ate.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.